Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Dermatological Medicine
Volume 2014, Article ID 563261, 4 pages
http://dx.doi.org/10.1155/2014/563261
Case Report

A Case of Onychomycosis Caused by Rhodotorula glutinis

1Department of Clinical Microbiology, Faculty of Medicine, Turgut Ozal University, Emek, 06510 Ankara, Turkey
2Department of Dermatology, Faculty of Medicine, Turgut Ozal University, Emek, 06510 Ankara, Turkey
3Mycology Reference Laboratory, Public Health Institution of Turkey, Sıhhıye, 06100 Ankara, Turkey

Received 31 July 2014; Accepted 16 September 2014; Published 25 September 2014

Academic Editor: Alireza Firooz

Copyright © 2014 Hatice Uludag Altun et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Rhodotorula spp. have emerged as opportunistic pathogens, particularly in immunocompromised patients. The current study reports a case of onychomycosis caused by Rhodotorula glutinis in a 74-year-old immunocompetent female. The causative agent was identified as R. glutinis based on the pinkish-orange color; mucoid-appearing yeast colonies on Sabouraud Dextrose Agar at 25°C; morphological evaluation in the Corn Meal-Tween 80 agar; observed oval/round budding yeast at 25°C for 72 hours; no observed pseudohyphae; positive urease activity at 25°C for 4 days; and assimilation features detected by API ID 32C kit and automated Vitek Yeast Biochemical Card 2 system. Antifungal susceptibility test results were as follows: amphotericin B (MIC = 0.5 µg/mL), fluconazole (MIC = 128 µg/mL), itraconazole (MIC = 0.125 µg/mL), voriconazole (MIC = 1 µg/mL), posaconazole (MIC = 0.5 µg/mL), anidulafungin (MIC = 0.5 µg/mL), and caspofungin (MIC = 16 µg/mL). Antifungal therapy was initiated with oral itraconazole at a dose of 400 mg/day; seven-day pulse therapy was planned at intervals of three weeks. Clinical recovery was observed in the clinical evaluation of the patient before the start of the third cure. Although R. glutinis has rarely been reported as the causative agent of onychomycosis, it should be considered.